论文部分内容阅读
目的研究克拉霉素联合头孢哌酮舒巴坦对慢性阻塞性肺疾病(COPD)合并下呼吸道感染患者的疗效及预后。方法 106例被诊断为COPD合并下呼吸道感染患者,以随机数字法分成观察组(53例)和对照组(53例)。对照组给予头孢哌酮舒巴坦进行治疗,观察组在此基础上另给予克拉毒素进行联合治疗,比较两组疗效以及预后。结果观察组治疗显效率为69.81%,总有效率为96.23%,均显著高于对照组的45.28%、81.13%(P<0.05);观察组肺功能改善情况显著优于对照组(P<0.05);观察组不良情况比对照组少,但差异无统计学意义(P>0.05)。结论克拉霉素联合头孢哌酮舒巴坦治疗COPD合并下呼吸道感染疗效高,能显著改善患者肺功能,且不良反应少,值得临床推广。
Objective To investigate the efficacy and prognosis of clarithromycin combined with cefoperazone sulbactam in patients with chronic obstructive pulmonary disease (COPD) complicated with lower respiratory tract infection. Methods One hundred and six patients were diagnosed as COPD patients with lower respiratory tract infection and divided into observation group (n = 53) and control group (n = 53) by random number method. The control group was given cefoperazone sulbactam for treatment. On the basis of this, the observation group was additionally treated with clarithromycin, and the curative effect and prognosis of the two groups were compared. Results The effective rate of observation group was 69.81%, the total effective rate was 96.23%, which were significantly higher than that of control group (45.28%, 81.13%, P <0.05). The improvement of pulmonary function in observation group was significantly better than that of control group ). The observation group had fewer adverse reactions than the control group, but the difference was not statistically significant (P> 0.05). Conclusion Clarithromycin and cefoperazone sulbactam are effective in treating COPD with lower respiratory tract infection, and can significantly improve pulmonary function in patients with less adverse reactions, which is worthy of clinical promotion.